NCT06526182View on ClinicalTrials.gov

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

PHASE3RecruitingINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

July 3, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Dermatitis, AtopicEczema
Interventions
BIOLOGICAL

Lebrikizumab

Lebrikizumab solution for injection administered subcutaneously.

OTHER

Placebo

Lebrikizumab Matching placebo solution for injection administered subcutaneously.

Trial Locations (4)

Unknown

RECRUITING

Hospital General Universitario Dr. Balmis, Alicante

RECRUITING

Hospital del Mar - Parc de Salut Mar, Barcelona

RECRUITING

Hospital Universitario Clínico San Cecilio, Granada

RECRUITING

Consorci Hospital General Universitari de València, Valencia

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY